Amsterdam, The Netherlands, January 23, 2017. It is with great pleasure that LSP, the specialist European healthcare investment firm, announces that its portfolio company G-Therapeutics has been named by FierceBiotech as one of FierceMedicalDevices' 2016 Fierce 15 companies, designating it as one of the most promising private medtech companies in the industry.
G-Therapeutics announced in April 2016 that it raised EUR 36 million to develop its novel neuro-stimulation therapy for people with spinal cord injuries. G-Therapeutics is a spin-off from the lab of Professor Grégoire Courtine at École Polytechnique Fédérale de Lausanne (EPFL), with offices in Eindhoven, the Netherlands, and Lausanne, Switzerland. The Series A investment round was co-led by LSP, INKEF Capital, Gimv and Wellington Partners, with the goal to bring a unique, new therapy for improved rehabilitation of spinal-cord injuries from the lab to patients. In particular, G-Therapeutics is developing a unique, implantable neuro-stimulation system for electrical stimulation of specific areas of the spinal cord with real-time motion feedback, and intent-driven rehabilitation.
FierceBiotech is an internationally recognized daily report reaching a network of over 165,000 biotech and medtech professionals, providing subscribers with an authoritative analysis of the day’s top stories. Every year, hundreds of private biotech and medtech companies are evaluated from around the world for its annual Fierce 15 lists, which are based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
The complete FierceMedicalDevices' 2016 Fierce 15 list can be found at: www.fiercebiotech.com
FierceBiotech is the biotech and medtech industries’ daily monitor, email newsletter and web resource providing the latest biotech and medtech news, articles, and resources. More than 165,000 top biotech and medtech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com.
LSP is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. With over EUR 1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors. For more information, please visit www.lspvc.com.